骨骼健康与含糖皮质激素的淋巴瘤治疗——危险因素与预防措施综述
本文综述糖皮质激素诱导的骨质疏松症(GIO)在淋巴瘤患者中的病理生理、观察性一线研究中的风险及前瞻性临床试验中预防措施的疗效,并基于现有文献提出淋巴瘤中GIO风险评估与管理的建议。
要点
- 含糖皮质激素的免疫化疗后,相当比例淋巴瘤患者发生骨折相关事件或需二级骨骼预防。
- 综述总结了GIO的病理生理及观察性一线淋巴瘤研究中的GIO风险。
- 基于现有文献提供淋巴瘤中GIO风险评估与管理的建议。
核心结论
- 骨折相关事件或需二级骨骼预防在相当比例接受常规含类固醇免疫化疗的淋巴瘤患者中具有临床意义,可能与GIO相关。
研究设计与样本
- 综述:描述GIO的病理生理,总结观察性一线淋巴瘤研究中的GIO风险及多项前瞻性临床试验中预防措施的疗效,并基于现有文献提供GIO风险评估与管理建议。
主要发现
- 近期发表的人群和回顾性系列研究强调在淋巴瘤治疗患者中考虑骨骼健康的重要性。
- 骨折相关事件或需二级骨骼预防可能与GIO相关,在相当比例接受常规含类固醇免疫化疗的淋巴瘤患者中具有临床意义。
临床怎么用
- 基于当前可用文献提供淋巴瘤中GIO风险评估与管理的建议。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
With survival outcomes ever improving for patients with a wide range of lymphoma histologies, the focus on reducing long-term complications of therapy has increased. Recently published, complimentary population and retrospective series have highlighted the importance of considering bone health in patients treated for lymphoma. Fracture-related events or the requirement for secondary bone prophylaxis, likely linked to glucocorticoid-induced osteoporosis (GIO) are substantial and clinically meaningful in a significant minority of patients following routinely employed steroid-containing immunochemotherapy. In this review, we describe the pathophysiology of GIO, the risk of GIO in observational front-line lymphoma studies and efficacy of prophylactic measures from several prospective clinical trials are summarized. Finally, areas of importance for future research are discussed and recommendations for GIO risk assessment and management in lymphoma are provided based on the current available literature.
引用
- Eyre TA, Jensen P, Booth S, et al. Bone health and glucocorticoid-containing lymphoma therapy - a review of risk factors and preventative measures. Br J Haematol. 2022. PMID: 35235226. doi:10.1111/bjh.18104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。